Please assess the completion status of the following clinical trial:

Trial Title: A Randomized, Double-Blind, Placebo-Controlled, 3x3 Factorial Design, Phase II Study to Evaluate the Antihypertensive Efficacy and Safety of Combination of Fimasartan and Amlodipine in Patients With Essential Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 9.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects who agreed to participate in this study and submitted the written informed consent~2. Subjects aged 20 to 75 years~3. Essential hypertension subjects who are measured more 90mmHg, less than 114mmHg of sitting diastolic blood pressure (SiDBP) at baseline(day 0).~4. Subjects who considered to understand this study , be cooperative, and able to be followed-up whole of the study period.~Exclusion Criteria:~1. Severe hypertension patients; more 115mmHg of SiDBP and/or more 185 mmHg of Sitting systolic blood pressure (SiSBP)~2. Patients with secondary hypertension~3. Patients with significant investigations - abnormal renal function (Creatinine more 1.5 times than upper limit of normal), abnormal liver function (AST, ALT more 2 times than upper normal), moderate fatty lever needed medication~4. Patients with significant investigations - Hypokalemia(Less than 3.5mmol/L), Hyperkalemia(exceeded 5.5mmol/L)~5. Patients with sodium ion or body fluid is depleted and not able to correct~6. Patients with hypotension who has sign and symptom~7. Patients with surgical and medical disease it is able to be affect to absorption, distribution, metabolism, excretion~8. Patients with severe insulin dependent or uncontrolled diabetes mellitus (HbA1c \> 9%, regimen change of oral hypoglycemic agent, using insulin)~9. Patients with severe heart disease, ischemic heart disease within 6months, peripheral vascular disease, Percutaneous Transluminal Coronary Angiography (PTCA), Coronary Artery Bypass Graft (CABG)~10. Patients with significant ventricular tachycardia, atrial fibrillation, atrial flutter or other significant arrhythmia~11. Patients with hypertrophic obstructive cardiomyopathy, severe obstructive coronary artery disease, aortic stenosis, hemodynamically significant aortic valve or mitral valve disease~12. Patients with severe cerebrovascular disease~13. Patients with wasting disease, autoimmune disease, connective tissue disease at present and/or previous.~14. Patients with known severe or malignancy retinopathy~15. Patients with hepatitis B or C or HIV positive reaction~16. Patients who have a story or evidence of alcohol or drug abuse within 2years~17. Patients who are measured the mean difference of mean blood pressure of both arm under SiDBP 10mmHg or SiSBP 20mmHg at screening and baseline visit~18. Patients with history of allergic reaction to any angiotensin II antagonist~19. Patients with any chronic inflammation disease needed to chronic inflammation therapy~20. Patients with the medical histories of malignant tumor within 5years, except local basal cell carcinoma of the skin~21. Childbearing and breast-feeding women~22. Female who plan to become pregnancy or have a possibility of pregnancy but don't prevent conception with acknowledged methods~23. Patients who took medicine within 12 weeks from screening visit or is going on the progress of other clinical trial~24. Subject who are judged unsuitable to participate in this study by investigator

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Take one double-blind capsule filled with a placebo tablet in the every morning
- Fimasartan 60mg (Type: ACTIVE_COMPARATOR): Take one double-blind capsule filled with of Fimasartan 60mg in the every morning
- Fimasartan 30mg (Type: ACTIVE_COMPARATOR): Take one double-blind capsule filled with Fimasartan 30mg in the every morning
- Amlodipine 5mg (Type: ACTIVE_COMPARATOR): Take one double-blind capsule filled with Amlodipine 5mg in the every morning
- Amlodipine 10mg (Type: ACTIVE_COMPARATOR): Take one double-blind capsule filled with Amlodipine 10mg in the every morning
- Fimasartan 60mg/ Amlodipine 5mg (Type: EXPERIMENTAL): Take one double-blind capsule filled with Fimasartan 60mg and Amlodipine 5mg in the every morning
- Fimasartan 60mg/Amlodipine 10mg (Type: EXPERIMENTAL): Take one double-blind capsule filled with Fimasartan 60mg and Amlodipine 10mg in the every morning
- Fimasartan 30mg/Amlodipine 5mg (Type: EXPERIMENTAL): Take one double-blind capsule filled with Fimasartan 30mg and Amlodipine 5mg in the every morning
- Fimasartan 30mg/Amlodipine 10mg (Type: EXPERIMENTAL): Take one double-blind capsule filled with Fimasartan 30mg and Amlodipine 10mg in the every morning

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete